GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nexentis Technologies NXTS · USD

US listing · 🇺🇸 United States

Compare

2.51

+387.16%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nexentis Technologies

From its filings with the US Securities and Exchange Commission

SEC filings

Nexentis Technologies is based in New York, New York and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker NXTS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2024, it reported revenue of $210,000.

Read the filing on SEC.gov ↗

Company facts

Listed since
18 Oct 2017
Head office
156 FIFTH AVENUE 10TH FLOOR, NEW YORK, NY, 10010-7751
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Nexentis Technologies Inc. develops MITOLINE for mitochondrial carrier protein modeling.
  • The company operates Biotechnology Activity and Renewable Energy Projects segments.
  • Nexentis Technologies Inc. has a pipeline including cloud-based computational chemistry platforms.

Weaknesses

  • Nexentis Technologies Inc. was formerly known as N2OFF, Inc. before 2026.
  • The company's headquarters is in Ness Ziona, Israel, not the US.
  • Nexentis Technologies Inc. was incorporated in 2009, not recently.

Opportunities

  • Nexentis Technologies Inc. can expand its Biotechnology Activity segment in the US market.
  • The company's MITOLINE algorithm could be applied in cancer research globally.
  • Renewable Energy Projects segment offers potential growth in sustainable energy markets.

Threats

  • Nexentis Technologies Inc. faces competition in the Biotechnology Activity segment.
  • The company's Renewable Energy Projects segment may encounter regulatory challenges.
  • Nexentis Technologies Inc. must address challenges in the US market for its products.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.